376 related articles for article (PubMed ID: 8388491)
1. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus type 16 E6, human mdm-2, and mutant p53.
Hoppe-Seyler F; Butz K
J Virol; 1993 Jun; 67(6):3111-7. PubMed ID: 8388491
[TBL] [Abstract][Full Text] [Related]
2. Repression of human papillomavirus oncogenes in HeLa cervical carcinoma cells causes the orderly reactivation of dormant tumor suppressor pathways.
Goodwin EC; DiMaio D
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12513-8. PubMed ID: 11070078
[TBL] [Abstract][Full Text] [Related]
3. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells.
Ristriani T; Fournane S; Orfanoudakis G; Travé G; Masson M
Oncogene; 2009 Feb; 28(5):762-72. PubMed ID: 19015633
[TBL] [Abstract][Full Text] [Related]
4. p53-independent growth regulation of cervical cancer cells by the papillomavirus E6 oncogene.
Spitkovsky D; Aengeneyndt F; Braspenning J; von Knebel Doeberitz M
Oncogene; 1996 Sep; 13(5):1027-35. PubMed ID: 8806692
[TBL] [Abstract][Full Text] [Related]
5. Human papillomavirus 16 E6 expression disrupts the p53-mediated cellular response to DNA damage.
Kessis TD; Slebos RJ; Nelson WG; Kastan MB; Plunkett BS; Han SM; Lorincz AT; Hedrick L; Cho KR
Proc Natl Acad Sci U S A; 1993 May; 90(9):3988-92. PubMed ID: 8387205
[TBL] [Abstract][Full Text] [Related]
6. Expression of the Long Noncoding RNA DINO in Human Papillomavirus-Positive Cervical Cancer Cells Reactivates the Dormant TP53 Tumor Suppressor through ATM/CHK2 Signaling.
Sharma S; Munger K
mBio; 2020 Jun; 11(3):. PubMed ID: 32546626
[TBL] [Abstract][Full Text] [Related]
7. Reversible repression of papillomavirus oncogene expression in cervical carcinoma cells: consequences for the phenotype and E6-p53 and E7-pRB interactions.
von Knebel Doeberitz M; Rittmüller C; Aengeneyndt F; Jansen-Dürr P; Spitkovsky D
J Virol; 1994 May; 68(5):2811-21. PubMed ID: 8151752
[TBL] [Abstract][Full Text] [Related]
8. The presence of human papillomavirus-16/-18 E6, p53, and Bcl-2 protein in cervicovaginal smears from patients with invasive cervical cancer.
Pillai MR; Halabi S; McKalip A; Jayaprakash PG; Rajalekshmi TN; Nair MK; Herman B
Cancer Epidemiol Biomarkers Prev; 1996 May; 5(5):329-35. PubMed ID: 9162297
[TBL] [Abstract][Full Text] [Related]
9. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
10. [Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma].
Bian J; Yu X; Dong J; Zhao W; Zhou Y; Luan Y
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):271-3. PubMed ID: 15617346
[TBL] [Abstract][Full Text] [Related]
11. Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of the human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells.
Hu G; Liu W; Hanania EG; Fu S; Wang T; Deisseroth AB
Cancer Gene Ther; 1995 Mar; 2(1):19-32. PubMed ID: 7621252
[TBL] [Abstract][Full Text] [Related]
12. Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
López-Ocejo O; Viloria-Petit A; Bequet-Romero M; Mukhopadhyay D; Rak J; Kerbel RS
Oncogene; 2000 Sep; 19(40):4611-20. PubMed ID: 11030150
[TBL] [Abstract][Full Text] [Related]
13. Induction of the p53-target gene GADD45 in HPV-positive cancer cells.
Butz K; Whitaker N; Denk C; Ullmann A; Geisen C; Hoppe-Seyler F
Oncogene; 1999 Apr; 18(14):2381-6. PubMed ID: 10327059
[TBL] [Abstract][Full Text] [Related]
14. Extended effects of human papillomavirus 16 E6-specific short hairpin RNA on cervical carcinoma cells.
Bai L; Wei L; Wang J; Li X; He P
Int J Gynecol Cancer; 2006; 16(2):718-29. PubMed ID: 16681752
[TBL] [Abstract][Full Text] [Related]
15. G2 checkpoint in uterine cervical cancer with HPV 16 E6 according to p53 polymorphism and its screening value.
Cho NH; Lim SY; Kim YT; Kim D; Kim YS; Kim JW
Gynecol Oncol; 2003 Jul; 90(1):15-22. PubMed ID: 12821336
[TBL] [Abstract][Full Text] [Related]
16. Transactivation-competent bovine papillomavirus E2 protein is specifically required for efficient repression of human papillomavirus oncogene expression and for acute growth inhibition of cervical carcinoma cell lines.
Goodwin EC; Naeger LK; Breiding DE; Androphy EJ; DiMaio D
J Virol; 1998 May; 72(5):3925-34. PubMed ID: 9557678
[TBL] [Abstract][Full Text] [Related]
17. Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation.
Razani B; Altschuler Y; Zhu L; Pestell RG; Mostov KE; Lisanti MP
Biochemistry; 2000 Nov; 39(45):13916-24. PubMed ID: 11076533
[TBL] [Abstract][Full Text] [Related]
18. The role of HPV oncoproteins and cellular factors in maintenance of hTERT expression in cervical carcinoma cells.
Jeong Seo E; Jung Kim H; Jae Lee C; Tae Kang H; Seong Hwang E
Gynecol Oncol; 2004 Jul; 94(1):40-7. PubMed ID: 15262117
[TBL] [Abstract][Full Text] [Related]
19. The state of p53 in primary human cervical carcinomas and its effects in human papillomavirus-immortalized human cervical cells.
Chen TM; Chen CA; Hsieh CY; Chang DY; Chen YH; Defendi V
Oncogene; 1993 Jun; 8(6):1511-8. PubMed ID: 8389030
[TBL] [Abstract][Full Text] [Related]
20. Human Papillomavirus 16 Oncoprotein Expression Is Controlled by the Cellular Splicing Factor SRSF2 (SC35).
McFarlane M; MacDonald AI; Stevenson A; Graham SV
J Virol; 2015 May; 89(10):5276-87. PubMed ID: 25717103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
